RecruitingPhase 3NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Loxo Oncology, Inc.
- Principal Investigator
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)Eli Lilly and Company
- Intervention
- Pirtobrutinib(drug)
- Enrollment
- 662 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2028
Study locations (30)
- Pacific Cancer Medical Center, Inc, Anaheim, California, United States
- TOI Clinical Research, Cerritos, California, United States
- Stanford School of Medicine-Cancer Clinical Trials Office, Palo Alto, California, United States
- California Cancer Associates for Research and Excellence, San Marcos, California, United States
- Florida Cancer Specialists, Fort Myers, Florida, United States
- Cancer Specialists of North Florida -St Augustine, Saint Augustine, Florida, United States
- Florida Cancer Specialists East, West Palm Beach, Florida, United States
- Hematology Oncology Clinic, Baton Rouge, Louisiana, United States
- Tulane Cancer Center Office of Clinical Research, New Orleans, Louisiana, United States
- American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
- St. Vincent Frontier Cancer Center, Billings, Montana, United States
- Cancer Care Associates of York, York, Pennsylvania, United States
- Prisma Health Cancer Institute, Greenville, South Carolina, United States
- Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States
- Kelsey Research Foundation, Houston, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05254743 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn